Amryt Pharma
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 31 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Amryt Pharma's reported carbon emissions
In 2023, Amryt Pharma reported total carbon emissions of approximately 1,004,680 kg CO2e, comprising 29,906,000 kg CO2e from Scope 1, 591,000 kg CO2e from Scope 2, and 949,619,000 kg CO2e from Scope 3 emissions. This reflects a slight increase in Scope 1 emissions compared to 2022, where they were about 29,715,000 kg CO2e, while Scope 2 emissions decreased from 822,000 kg CO2e. The Scope 3 emissions also rose from 897,564,000 kg CO2e in 2022. Amryt Pharma has disclosed emissions data across all three scopes, indicating a commitment to transparency in their climate impact. However, there are currently no specific reduction targets or initiatives outlined in their reports. The company continues to monitor and report its emissions, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 27,507,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,771,000 | 000,000 | 000,000 |
| Scope 3 | 815,059,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amryt Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
